Elaine Sullivan

Bristol Myers Squibb

Cari Gallman

Bristol Myers Squibb has appointed Cari Gallman as executive vice president, general counsel and chief policy officer. Gallman has held leadership positions at Bristol Myers Squibb for ten years, most recently serving as executive vice president, corporate affairs. She was also previously chief compliance and ethics officer at the company.

leon-nanodrugs

Wolfgang Hofmann

leon-nanodrugs has appointed Wolfgang Hofmann as chief executive officer. Hofmann brings extensive industry experience to the role, having recently served in executive roles covering mergers and acquisitions, venture capital and innovation management at Fresenius Group. He also previously held multiple senior positions at Novartis.

VERAXA Biotech

Rick Austin

VERAXA Biotech has appointed Rick Austin as chief scientific officer. Austin holds over 25 years of experience across oncology discovery and early development, and most recently served as vice president, research at Harpoon Therapeutics, after holding the position of senior director, biology research at the company. He also previously held multiple positions at Amgen.

STORM Therapeutics

Atif Abbas

STORM Therapeutics has appointed Atif Abbas as chief medical officer. Abbas has two decades of industry experience and joins STORM after serving as vice president at Servier Pharmaceuticals. He was also previously vice president, head of oncology and immunology at Spring Bank Pharmaceuticals, and held roles at AbbVie, Astellas and Boehringer Ingelheim.

Daiser

Dominic James

Daiser has appointed Dominic James as a member of its advisory board. James brings over three decades of industry experience to the role. He previously held multiple senior positions at Merck, including global head of digital health innovation and alliances. He also founded Future Centric last year and serves as its chief executive officer.

Commit Biologics

Janine Schuurman

Commit Biologics has appointed Janine Schuurman as co-chair of its scientific advisory board. Schuurman is a molecular immunologist who previously spent over two decades at Genmab, most recently as senior vice president, head of antibody research and technology. She also currently serves as president and a board member of the Antibody Society.

Commit Biologics

Gavin Thurston

Commit Biologics has appointed Gavin Thurston as a member of its scientific advisory board. Thurston holds over 20 years of experience in oncology research and previously served as senior vice president of oncology research at Regeneron. He also serves on the scientific advisory boards of Rondo Therapeutics and AbTherx, and is an advisor at Voyant Bio.

Priothera

Hans Menssen

Priothera has appointed Hans Menssen to its board of directors. Menssen most recently served as senior global programme clinical head at Novartis Oncology. Prior to this, he held the position of chief medical officer at Philogen, and was senior director, clinical development oncology at Bayer Pharmaceuticals earlier in his career.